Clinical Trials Logo

Clinical Trial Summary

In order to treat proliferative IgA Nephropathy(IgAN), The investigators designed an open, prospective, randomized parallel study to access the efficacy and safety of MMF compared to corticosteroid .

Patients who fulfill the inclusion criteria will be randomized in a 1:1 ratio to either the MMF group or corticosteroid group.


Clinical Trial Description

To access the efficacy and safety of MMF compared to corticosteroid in in treatment of proliferative IgA Nephropathy(IgAN). ;


Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment


Related Conditions & MeSH terms


NCT number NCT01269021
Study type Interventional
Source Nanjing University School of Medicine
Contact
Status Completed
Phase N/A
Start date November 2010
Completion date April 2014

See also
  Status Clinical Trial Phase
Terminated NCT03841448 - A Study of Cemdisiran in Adults With Immunoglobulin A Nephropathy (IgAN) Phase 2
Completed NCT04689074 - Establishment of the Human Intestinal and Salivary Microbiota Biobank - Kidney Diseases